hMPV Z high dose vaccine

The **hMPV Z high dose vaccine** is an investigational recombinant protein subunit vaccine developed by **GSK** for the prevention of human metapneumovirus (hMPV) infection. It is being evaluated in Phase 1/2 clinical trials (such as NCT04141540) as a standalone vaccine candidate. The vaccine typically utilizes the hMPV fusion (F) protein, often stabilized in its prefusion conformation, to elicit high titers of neutralizing antibodies. The "Z" designation refers to a specific formulation variant, likely involving a particular adjuvant system (such as GSK's AS01), administered at a high dose to assess safety, reactogenicity, and immunogenicity in younger adults (18–49 years) and older adults (60–80 years). This candidate is part of a broader program by GSK to develop vaccines against major respiratory pathogens, including standalone and combination vaccines for hMPV and respiratory syncytial virus (RSV).

Other names

hMPV_Z high dose vaccineGSK investigational hMPV vaccine